Patient Advocacy Groups Take in Millions from Drugmakers. Is There a Payback?

April 9, 2018

(Kaiser Health News) – Pharmaceutical companies gave at least $116 million to patient advocacy groups in a single year, reveals a new database logging 12,000 donations from large publicly traded drugmakers to such organizations. Even as these patient groups grow in number and political influence, their funding and their relationships to drugmakers are little understood. Unlike payments to doctors and lobbying expenses, companies do not have to report payments to the groups.

Recommended Reading